Could azithromycin prevent NHS workers from developing COVID-19?

Do you think azithromycin or doxycycline administered daily to frontline NHS workers prevent them from developing COVID-19? Researchers from the University of Salford tell us more.

Hope has been raised for NHS workers as a potential treatment for the corona virus may be on the horizon. Professor Michael P Lisanti and colleagues from the University of Salford, UK, are proposing a new mechanistic framework for understanding how ageing and senescence could contribute to the lethality of COVID-19 in older patients, suggesting the use of anti-ageing drugs as a new clinical approach. Many of these MHRA/FDA-approved drugs are antibiotics, such as doxycycline and azithromycin, which strongly inhibit both inflammation and viral replication, by blocking protein synthesis as a side effect.

A cost of as little as 10p per patient per day

“We have identified several classes of existing MHRA/FDA-approved drugs that, we believe, will help to target the COVID-19 corona virus, for both preventing and treating the disease and at a very low cost to the NHS,” according to lead author Professor Lisanti.

Professor Lisanti is the Chair of Translational Medicine at the University of Salford; and his laboratory has previously published groundbreaking work on the molecular basis of normal ageing, called cellular senescence, and how removing senescent cells with ‘senolytic’ drugs could prevent and possibly reverse ageing-associated diseases.

Interestingly, his latest commentary article discusses how senescent cells may be the key to understanding how to treat COVID-19 infections, with MHRA/FDA-approved drugs. Professor Lisanti and his team propose that these drugs could be effective and would be readily available, with a cost of as little as 10 pence per patient per day.

Azithromycin treating COVID-19 infections

One of the proposed drugs is the antibiotic azithromycin, which is widely used to treat chest, sinus, throat and skin infections, as well as sexually transmitted diseases.

Professor Lisanti adds: “Azithromycin is known to stop the production of cytokines, a torrent of inflammatory mediators that trigger life-threatening lung inflammation in corona virus patients; azithromycin has also been shown to block the production of other viruses, such as the Zika and Ebola viruses”.

In combination with hydroxychloroquine, azithromycin was recently shown to inhibit the replication of the COVID-19 corona virus, in a clinical trial in France. However, the effects of azithromycin alone were not assessed.

Senescence and COVID-19

Looking at the host receptors of COVID-19, they are related to senescence. Two proteins have been proposed to be the cellular receptors of COVID-19: one is CD26 – a marker of senescence, and the other, ACE-2, is also associated with senescence. Therefore, older people would be predicted to be more susceptible to COVID-19, exactly as is observed clinically in patients. This could increase their probability of infection, and would explain the increased fatality of COVID-19 infection in older patients. All of this could be related to advanced chronological age and senescent cells.

Professor Lisanti explains: “If that is the case, then we could intervene, by targeting and removing senescent cells or by using other classes of anti-ageing drugs, to reduce the serious inflammatory reaction caused by the SASP (senescence-associated secretory phenotype). This has the potential to prevent COVID-19 transmission and to ameliorate the associated life-threatening symptoms.”

So how do you remove senescent cells? By administering senolytic drugs, many of which are existing FDA/MHRA approved drugs. Azithromycin is FDA/MHRA approved, and it is used mainly for lung infections, but the Lisanti laboratory found that it selectively targets and removes 97% of the senescent cells.

Vaccines could be 18 to 24 months away, so it would be necessary to identify MHRA/FDA approved drug candidates to repurpose for the prevention and treatment of COVID-19 disease, while we wait.

Now, we need to put these drugs into clinical trials. They are already considered safe, as they have passed Phase 1 clinical trials, so we have absolutely nothing to lose.

Watch the full interview below:

We need to put these drugs into clinical trials

One of the first clinical studies published in the Lancet, showed that COVID-19 infections were most lethal in patients with advanced age, or ageing-associated diseases (diabetes and heart disease), with an elevation of IL-6, a key marker of senescence-associated inflammation.

Clinically, it appears what is leading to fatalities in older patients is the very strong inflammatory reaction and the resulting fibrosis. Azithromycin inhibits inflammation-induced fibrosis, by targeting and removing senescent cells. The cost would be minimal, as the drug is off-patent, widely available and considered safe.

Other senescence-related and anti-ageing drugs, such rapamycin, doxycycline, and hydroxychloroquine could be made available, with support of the relevant regulatory authorities.

For example, in the United States, FDA-approved drugs can be medically prescribed for an ‘off-label’ use, at the discretion of the practising physician.

Unfortunately, the longer we wait, the more people will die. There are not enough respirators, so we need to do something innovative, with great urgency.

Inhibitor(s) of protein synthesis block inflammation and viral replication. Mechanistically, this is because cytokines and viruses are both made of proteins. Both use the cellular ribosomes for protein synthesis. Inhibiting virus production should help to clinically reduce viral transmission to other patients.

Recommended Related Articles

Michael Lisanti and his focus on doxycycline antibiotics

Michael Lisanti and antibiotics: the next cancer revolution

Success: effects of antibiotics in breast cancer clinical trial

Drug candidate identified to starve and suffocate breast cancer stem cells